Document:

Amendment to Distribution and Manufacturing Services Agreement

 Exhibit 10.5 
 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit
has been filed separately with the Securities and Exchange Commission. 
 June 18, 2009 
 Dr. Robert Tiebout 
 The Sanquin Blood Supply Foundation 
 Plesmanlaam 125 
 1 066CX Amsterdam 
 The Netherlands 
 Dear Dr. Tiebout 
 Reference is
made to the Distribution and Manufacturing Services Agreement between Lev Pharmaceuticals Inc. (“Lev”) and Sanquin Blood Supply Foundation (“Sanquin) dated January 16, 2004, as amended through the date hereof (the “DMS
Agreement”). ViroPharma Biologics, Inc. (“ViroPharma”) is the successor to Lev under the DMS Agreement. All capitalized terms used in this letter agreement (this “Agreement”) that are not defined below shall have the
meanings ascribed to them in the DMS Agreement. 
 Parties have evaluated the requirements made by *** and pursuant to supplements submitted to the BLA for
Cinryze. It was concluded that additional resources are needed to meet such requirements and that a revision of the purchase price for Cinryze is warranted. 
 Below you will find a brief description of the additional resources as discussed and the understanding between the parties in this respect. 
  

	1.	Equipment Purchase. 

 Part of the additional resources that were not
foreseen before relate to equipment. 
 Sanquin and ViroPharma agree that it is in the best interests of the parties for Sanquin to purchase a *** and to ***
to the *** for *** (“***”) system as well as to the *** system (“***”) (collectively, the “Equipment”) for use in manufacturing Cinryze for ViroPharma. 
 Sanquin shall purchase the Equipment, install it and qualify it for use in accordance with the timelines described in the Work Plan (defined below). 

	2.	Hiring of Additional Employees. 

 Another part of the additional
resources needed relate to staffing. 
 (a) Sanquin shall hire approximately *** additional full time equivalent employees (FTEs). The
FTE’s shall include persons hired in the following capacities: 
  

			
	 Function
	 	 FTEs

	 QA/QC
	 	***
	 Trend Analysis
	 	***
	 483 Follow Up
	 	***
	 Engineering/Qualification
	 	***
	 Look Back Handling
	 	***

 (b) *** of the FTEs shall include employees that will be dedicated to Cinryze manufacturing
efforts (the “Dedicated Employees”), and in the following capacities: 
 1) Project Manager/Coordinator and back-up. This
key role will provide: 
  

	 	•	 	 Overall project tracking, communication, and coordination. 

  

	 	•	 	 First point of contact for any questions relating to Cinryze that ViroPharma management and personnel may have. 

  

	 	•	 	 Key contact for all manufacturing/engineering projects and issues, responding to daily questions and issues. 

  

	 	•	 	 Update management on key issues, emerging concerns. 

  

	 	•	 	 Support the Supply Team administratively. 

 2) Regulatory Coordinator. This role communicates and coordinates all issues related to regulatory files and variations thereof, including all FDA and EMEA responses. 
 The FTEs shall be hired and trained in accordance with the Work Plan. 
  

	3.	Work Plan 

 (a) Equipment. Sanquin shall
accomplish the purchase, installation and qualification of the Equipment as follows: 
 (i) ***. Sanquin shall immediately undertake to
start a comprehensive study (as per commitments made to FDA pursuant to April 2009 audit in Brussels) for the ***, and shall submit a purchase order for the *** by ***. Assuming that the manufacturer of the *** delivers the equipment within ***
months after Sanquin orders it, and provided that the installation of the *** requires no re-design of Sanquin’s physical plant, then the *** shall be fully operational by ***. 
  

 2 

 (ii) *** Enhancements. The parties acknowledge that studies for the *** Enhancements are in progress.
The *** Enhancements shall be fully operational by ***. 
 (b) FTEs. The Dedicated Employees shall be appointed by ***. These shall
either be newly hired and trained employees or existing employees appointed in these positions and indicated to ViroPharma as prime point of contact. The next *** additional FTEs shall be hired and trained by ***. The hiring and training process for
the remaining *** additional FTE’s shall start as soon as it becomes clear that, based on demand for product as well as available manufacturing capacity, the volume of Cinryze toll manufactured on behalf of ViroPharma from USA plasma for the
next 12 month period shall be between *** and *** Units. 
 (c) Progress Reporting; Changes to Work Plan. The parties acknowledge that
they have formed a Joint Supply Team under the DMS Agreement. Sanquin’s representatives on the Joint Supply Team shall keep ViroPharma fully informed as to the status of Sanquin’s progress under the “Work Plan” described in this
Section 3. To the extent that circumstances arise that were not anticipated by the parties and that prevent Sanquin from accomplishing the tasks described in the Work Plan by the dates associated with those tasks under the Work Plan, the
parties shall meet and negotiate in good faith changes, if any, that are required to the Work Plan. 
  

	4.	Price for Product 

 (a) Subject to Section 4(b)
below, effective on the date that Sanquin informs ViroPharma in writing that it has hired and trained the first *** additional FTEs contemplated by Section 3, the price per vial of *** Units of Cinryze shall be as set forth below (price level
***, to be amended yearly, starting ***, with a percentage equal to the increase or decrease in the Dutch consumer price index.): 
  

			
	 Volume (Units) during each Twelve Month Period
	  	 Price (Euro)

	 *** – *** million
	  	***
	 *** million to *** million
	  	***
	 Over *** million
	  	***

 (b) Sanquin shall use best efforts to purchase, install and qualify the Equipment as well as hire
and train the FTE’s as projected in the Work Plan. Should there be any delays, the Sanquin shall use best efforts to compensate for the effects of such delays in order to ensure that the effects of such delays on the supply of Cinryze to the
USA shall be none or minimal. If ViroPharma can demonstrate that delays in executing the Work Plan impede the operational readiness of the *** to *** by ***, then ViroPharma shall present data substantiating such claim to Sanquin and Parties shall
discuss such data in good faith. If Sanquin cannot demonstrate to ViroPharma reasonable satisfaction that the then-current status of its efforts are on track to ensure the *** to its *** will be operational by ***, then the price per vial of ***
Units of Cinryze shall, upon the next shipment of Cinryze to the USA, revert to the price that was in effect on the date immediately preceding the date of this Agreement (the “Immediately Preceding Price”), and shall remain at such
Immediately Preceding Price until the date that the applicable Equipment is purchased, installed and qualified, or the FTEs are hired and trained (such event, as the case may be, a “Remedying Event”). Upon the date that such Remedying
Event occurs, the price per vial of *** Units of Cinryze shall immediately revert to the price set forth in Section 4(a) above. 
  

 3 

	5.	Other 

 This Agreement may be executed in
counterparts, each of which shall be deemed an original but all of which shall constitute one in the same document. Further, this Agreement shall be governed and interpreted in accordance with the laws of the Netherlands. 
 This Agreement constitutes the entire understanding between the parties and supersedes all previous understandings, communications and representations,
whether written or oral, concerning the contents of this Agreement and it may not be amended, modified or waived unless set forth in writing signed by the parties. 
 Please signify your consent to this Agreement by signing this Agreement in the space indicated below and returning the same to my attention. 
  

			
	Very truly yours,
	
	ViroPharma Biologics, Inc.
		
	By:	 	 /s/ Daniel Soland

		 	Daniel Soland, Director

  

			
	ACCEPTED AND AGREED TO:
	
	SANQUIN BLOOD SUPPLY FOUNDATION
		
	By:	 	 /s/ Theo Buunen

	Name:	 	Theo Buunen
	Title:	 	

  

 4WellPoint, Inc. Board of Directors Compensation Program, as amended May 20, 2009

 Exhibit 10.7 
 WELLPOINT, INC. 
 BOARD OF DIRECTORS COMPENSATION PROGRAM 
 (AS AMENDED MAY 20, 2009) 
 CASH
COMPENSATION—Retainers 
 Annual Board Retainer: 
  

	 	•	 	 $50,000 for all Directors paid quarterly in advance (in four equal installments of $12,500) on January 1, April 1, July 1 and
October 1. 

 Additional Annual Retainer for Committee Chairs: 
  

	 	•	 	 $15,000 for the Chair of the Audit Committee of the Board of Directors paid quarterly in advance (in four equal installments of $3,750) on
January 1, April 1, July 1 and October 1. 

  

	 	•	 	 $10,000 for the Chair of each other Committee of the Board of Directors paid quarterly in advance (in four equal installments of $2,500) on
January 1, April 1, July 1 and October 1. 

 Additional Annual Retainer for the Chairman
of the Board of Directors 
  

	 	•	 	 $250,000 for the Chairman of the Board of Directors paid quarterly in advance (in four equal installments of $62,500) on
January 1, April 1, July 1 and October 1. 

 CASH COMPENSATION—Meeting Fees 
 Board of Directors Meetings: 
  

	 	•	 	 $2,000 for Board of Directors Meetings held in person 

  

	 	•	 	 $1,000 for Board of Directors Meetings held telephonically unless otherwise specified 

 Committee Meetings: 
  

	 	•	 	 $2,000 for the Audit Committee Meetings held in person 

  

	 	•	 	 $1,000 for the Audit Committee Meetings held telephonically unless otherwise specified 

  

	 	•	 	 $1,500 for all other Committee Meetings held in person 

  

	 	•	 	 $750 for all other Committee Meetings held telephonically unless otherwise specified 

 STOCK COMPENSATION 
 Annual Full Value Share Grant: 

Each Director will receive, subject to the deferral described below, an annual grant of the number of shares equal to five times the Annual Board
Retainer on the date of the WellPoint, Inc. annual meeting of shareholders. The number of shares of the Annual Full Value Share Grant will be calculated using the following formula: 
 [Annual Board Retainer X 5] divided by [the closing price of the WellPoint, Inc. common stock as reported on the New York Stock Exchange on the date of
the annual meeting of shareholders] = Number of shares of the Annual Full Value Share Grant. 
 Deferral of Full Value Share Grants: 
 Each Annual Full Value Share Grant will be deferred for a minimum period of 5 years from the date of the Grant (“Deferral Period”) in accordance
with the terms of the Director Deferred Compensation Plan. Such Grants shall not be distributed to the Directors until the earlier of the expiration of the Deferral Period or the date on which a Director ceases to be a member of the Board of
Directors. 

 Director Ownership Guidelines: 
 Each Director shall have the obligation to own at least $400,000 of WellPoint, Inc. common stock (including deferred shares and phantom stock, but not options) commencing on the later of May 3, 2007 or the fifth
anniversary of the date such Director became a member of the Board of Directors. 
 MISCELLANEOUS 
 Annual Physical Exam: 
 WellPoint, Inc.
will pay the cost of an annual physical examination for each Director. 
 Expenses: 
 WellPoint, Inc. will reimburse each Director for all travel, lodging and other expenses incurred in connection with the attendance at and/or participation
in any and all Board of Directors Meetings and Committee Meetings and related matters in accordance with the WellPoint, Inc. Travel and Entertainment Policy.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]